NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Merck Sharp & Dohme LLC
Taiho Oncology, Inc.
Sunshine Lake Pharma Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Novartis